AQST
What one share of Aquestive Therapeutics holds
Pharmaceutical Preparations
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.
Aquestive Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.45 |
|---|---|
| Profit | −$0.65 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.38 |
| Cash and investments | $0.78 |
| Debt | $0.44 |
| Book value | −$0.45 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $3.25 | −$2.96 | $0.09 | −$0.71 | — | $0.40 |
| 2019 | $2.07 | −$2.61 | $0.03 | −$2.40 | — | −$0.18 |
| 2020 | $1.36 | −$1.66 | $0.02 | −$1.37 | — | −$1.40 |
| 2021 | $1.33 | −$1.85 | $0.02 | −$0.89 | — | −$1.99 |
| 2022 | $0.98 | −$1.12 | $0.02 | −$0.22 | — | −$2.16 |
| 2023 | $0.83 | −$0.13 | $0.02 | −$0.12 | — | −$1.55 |
| 2024 | $0.66 | −$0.51 | $0.00 | −$0.41 | — | −$0.66 |
| 2025 | $0.42 | −$0.78 | $0.01 | −$0.50 | — | −$0.28 |